

## REPURCHASE OF C-RAD B-SHARES WEEK 32 - 2024

Between 5 and 9 of August 2024, C-RAD AB (publ) (LEI code 549300SPXLHF15W2CU25) has repurchased 70,000 own B-shares (ISIN: SE0002016352).

The repurchase is carried out in accordance with the Annual General Meeting's authorization to the Board to acquire shares in the Company. The purpose of the repurchase is to cover the Company's obligations under previously resolved incentive programs.

Date	Aggregated daily volume (number of shares):	Weighted average share price per day (SEK):	Total daily transaction value (SEK):
2024-08-05	4,500	41.2246	185,511
2024-08-06	7,000	41.6192	291,334
2024-08-07	7,000	42.7328	299,130
2024-08-08	45,069	43.1954	1,946,773
2024-08-09	6,431	43.3383	278,709
<b>Total:</b>	<b>70,000</b>	<b>42.8780</b>	<b>3,001,457</b>

All acquisitions have been carried out on Nasdaq Stockholm by Pareto on behalf of C-RAD. Following the above acquisitions, C-RAD AB holds a total of 158,500 class B-shares in treasury as per 9 August 2024, equivalent to 0.47 percent of the total number of shares outstanding, and 0.38 percent of the votes.

The total number of shares outstanding in C-RAD AB, including shares held in treasury, is 33,766,935, where of 862,887 are Class A-shares and 32,904,048 are Class B-shares.

### For further information:

---

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, [investors@c-rad.com](mailto:investors@c-rad.com)  
Jonas Reinhammar, Interim CFO, +46 (0)762 406 402, [investors@c-rad.com](mailto:investors@c-rad.com)

## About C-RAD

---

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

## Attachments

---

**Repurchase of C-RAD B-shares week 32 - 2024**